Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Arcoma

7.12 SEK

-1.93 %

Less than 1K followers

ARCOMA

First North Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
-1.93 %
-6.56 %
-20.89 %
-26.75 %
-33.77 %
-35.27 %
-7.53 %
-65.77 %
-46.54 %

Arcoma operates in the medical technology sector. The company is a developer and supplier of integrated digital X-ray systems. The company's products offer digital imaging technology combined with technically advanced mobile positioning systems. The products are sold through resellers and to a large proportion of OEM customers. Operations are found on a global level with sales primarily concentrated in Europe, Asia and North America. The head office is located in Växjö.

Read more
Market cap
101.88M SEK
Turnover
49.08K SEK
Revenue
156.81M
EBIT %
8.7 %
P/E
8.38
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
12/2
2026

Annual report '25

All
Press releases
3rd party
ShowingAll content types
Press release10/24/2025, 6:02 AM

DNB Carnegie Access: Arcoma: Europe muted, business mix supports margins – Q3 review

Arcoma
Regulatory press release10/23/2025, 6:30 AM

Kvartalsrapport Q3 – 2025. Stark efterfrågan i USA, Europa påverkat av avvaktande marknad (MAR)

Arcoma
Press release10/13/2025, 4:52 PM

DNB Carnegie Access: Arcoma: Sequential improvements but US uncertainty – Q3 preview

Arcoma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release9/5/2025, 8:00 AM

Arcoma AB inför incitamentsprogram kopplat till aktieköp för ledning och andra ledande befattningshavare i företaget.

Arcoma
Press release8/25/2025, 8:10 AM

DNB Carnegie Access: Arcoma: Intervju - Intervju efter Q2 2025

Arcoma
Press release8/22/2025, 6:00 AM

DNB Carnegie Access: Arcoma: US remains muted, easier comparisons in H2 – Q2 review

Arcoma
Regulatory press release8/21/2025, 6:30 AM

Kvartalsrapport Q2 2025 – Stark efterfrågan i Europa, USA påverkat av politiska faktorer. (MAR)

Arcoma
Press release7/8/2025, 1:02 PM

DNB Carnegie Access: Arcoma: Directed share issue, US to remain muted – Q2 preview

Arcoma
Regulatory press release6/30/2025, 6:30 AM

Arcoma avslutar avtal om likviditetsgaranti

Arcoma
Regulatory press release6/24/2025, 5:15 PM

Arcoma AB successfully completes directed share issue of SEK 11.0 million (~ EUR 1 million) (MAR)

Arcoma
Regulatory press release6/24/2025, 5:15 PM

Arcoma AB har framgångsrikt genomfört en riktad nyemission om 11,0 MSEK (~1 MEUR) (MAR)

Arcoma
Regulatory press release5/14/2025, 1:00 PM

Kommuniké från årsstämma i Arcoma Aktiebolag den 14 maj 2025

Arcoma
Press release4/29/2025, 2:39 PM

Carnegie Access: Arcoma: Solid gross margin, North America revenue declines – Q1 review

Arcoma
Regulatory press release4/29/2025, 6:30 AM

Kvartalsrapport Q1 2025 – Stark efterfrågan, installationstakt i USA dämpar kvartalet något. (MAR)

Arcoma
Regulatory press release4/3/2025, 5:15 PM

Rättelse: Årsredovisning 2024 är nu publicerad

Arcoma
Regulatory press release4/3/2025, 11:00 AM

Kallelse till årsstämma i Arcoma Aktiebolag

Arcoma
Regulatory press release4/3/2025, 11:00 AM

Årsredovisning 2024 är nu publicerad

Arcoma
Press release2/17/2025, 2:20 PM

Carnegie Access: Arcoma: Intervju - Avslutar 2024 med starka marginaler (rapportintervju Q4)

Arcoma
Press release2/14/2025, 7:48 AM

Carnegie Access: Arcoma: Margins expand, but Europe remains under pressure – Q4 review

Arcoma
Regulatory press release2/13/2025, 7:30 AM

Bokslutskommuniké 2024 – Vi avslutar 2024 med stark lönsamhet och summerar ett helår med rekordvinst. (MAR)

Arcoma
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.